Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
25
RGC Quote, Financials, Valuation and Earnings
Last price:
$4.90
Seasonality move
:
-17.94%
Day range:
$4.77 - $5.29
52-week range:
$3.03 - $32.44
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
7.79x
Volume:
2.1K
Avg. volume:
59.3K
1-year change:
-49.49%
Market cap:
$64M
Revenue:
--
EPS (TTM):
-$0.33
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RGC
Regencell Bioscience Holdings
|
-- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China)
|
-- | -- | -- | -- | $28.11 |
|
PHBBF
Pharmaron Beijing
|
-- | -- | -- | -- | -- |
|
PRE
Prenetics Global
|
$9.2M | -- | 128.43% | -- | $9.00 |
|
SBMFF
Sino Biopharmaceutical
|
-- | -- | -- | -- | -- |
|
UNBSF
Uni-Bio Science Group
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RGC
Regencell Bioscience Holdings
|
$4.92 | -- | $64M | -- | $0.00 | 0% | -- |
|
HCM
HUTCHMED (China)
|
$14.31 | $28.11 | $2.4B | 30.00x | $0.00 | 0% | 5.94x |
|
PHBBF
Pharmaron Beijing
|
$1.93 | -- | $2.5B | -- | $0.03 | 3.64% | 1.44x |
|
PRE
Prenetics Global
|
$5.65 | $9.00 | $69M | -- | $0.00 | 0% | 2.72x |
|
SBMFF
Sino Biopharmaceutical
|
$0.41 | -- | $7.5B | 24.26x | $0.00 | 2.49% | 1.97x |
|
UNBSF
Uni-Bio Science Group
|
-- | -- | -- | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RGC
Regencell Bioscience Holdings
|
-- | -5.973 | -- | -- |
|
HCM
HUTCHMED (China)
|
9.99% | -0.098 | 2.79% | 2.39x |
|
PHBBF
Pharmaron Beijing
|
-- | -0.376 | -- | -- |
|
PRE
Prenetics Global
|
-- | -1.149 | -- | 1.11x |
|
SBMFF
Sino Biopharmaceutical
|
22.46% | 0.228 | 18.85% | 1.07x |
|
UNBSF
Uni-Bio Science Group
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RGC
Regencell Bioscience Holdings
|
-- | -- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China)
|
-- | -- | -5.04% | -5.49% | -- | -- |
|
PHBBF
Pharmaron Beijing
|
-- | -- | -- | -- | -- | -- |
|
PRE
Prenetics Global
|
$3.9M | -$11.8M | -23.16% | -23.16% | -154.7% | -- |
|
SBMFF
Sino Biopharmaceutical
|
-- | -- | 8.21% | 10.53% | -- | -- |
|
UNBSF
Uni-Bio Science Group
|
-- | -- | -- | -- | -- | -- |
Regencell Bioscience Holdings vs. Competitors
-
Which has Higher Returns RGC or HCM?
HUTCHMED (China) has a net margin of -- compared to Regencell Bioscience Holdings's net margin of --. Regencell Bioscience Holdings's return on equity of -- beat HUTCHMED (China)'s return on equity of -5.49%.
Company Gross Margin Earnings Per Share Invested Capital RGCRegencell Bioscience Holdings-- -- -- HCMHUTCHMED (China)-- -- $834.1M -
What do Analysts Say About RGC or HCM?
Regencell Bioscience Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand HUTCHMED (China) has an analysts' consensus of $28.11 which suggests that it could grow by 96.4%. Given that HUTCHMED (China) has higher upside potential than Regencell Bioscience Holdings, analysts believe HUTCHMED (China) is more attractive than Regencell Bioscience Holdings.
Company Buy Ratings Hold Ratings Sell Ratings RGCRegencell Bioscience Holdings0 0 0 HCMHUTCHMED (China)9 2 0 -
Is RGC or HCM More Risky?
Regencell Bioscience Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison HUTCHMED (China) has a beta of 0.781, suggesting its less volatile than the S&P 500 by 21.86%.
-
Which is a Better Dividend Stock RGC or HCM?
Regencell Bioscience Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HUTCHMED (China) offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regencell Bioscience Holdings pays -- of its earnings as a dividend. HUTCHMED (China) pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RGC or HCM?
Regencell Bioscience Holdings quarterly revenues are --, which are smaller than HUTCHMED (China) quarterly revenues of --. Regencell Bioscience Holdings's net income of -- is lower than HUTCHMED (China)'s net income of --. Notably, Regencell Bioscience Holdings's price-to-earnings ratio is -- while HUTCHMED (China)'s PE ratio is 30.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regencell Bioscience Holdings is -- versus 5.94x for HUTCHMED (China). Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGCRegencell Bioscience Holdings-- -- -- -- HCMHUTCHMED (China)5.94x 30.00x -- --
-
Which has Higher Returns RGC or PHBBF?
Pharmaron Beijing has a net margin of -- compared to Regencell Bioscience Holdings's net margin of --. Regencell Bioscience Holdings's return on equity of -- beat Pharmaron Beijing's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RGCRegencell Bioscience Holdings-- -- -- PHBBFPharmaron Beijing-- -- -- -
What do Analysts Say About RGC or PHBBF?
Regencell Bioscience Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Pharmaron Beijing has an analysts' consensus of -- which suggests that it could fall by --. Given that Regencell Bioscience Holdings has higher upside potential than Pharmaron Beijing, analysts believe Regencell Bioscience Holdings is more attractive than Pharmaron Beijing.
Company Buy Ratings Hold Ratings Sell Ratings RGCRegencell Bioscience Holdings0 0 0 PHBBFPharmaron Beijing0 0 0 -
Is RGC or PHBBF More Risky?
Regencell Bioscience Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pharmaron Beijing has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RGC or PHBBF?
Regencell Bioscience Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharmaron Beijing offers a yield of 3.64% to investors and pays a quarterly dividend of $0.03 per share. Regencell Bioscience Holdings pays -- of its earnings as a dividend. Pharmaron Beijing pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RGC or PHBBF?
Regencell Bioscience Holdings quarterly revenues are --, which are smaller than Pharmaron Beijing quarterly revenues of --. Regencell Bioscience Holdings's net income of -- is lower than Pharmaron Beijing's net income of --. Notably, Regencell Bioscience Holdings's price-to-earnings ratio is -- while Pharmaron Beijing's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regencell Bioscience Holdings is -- versus 1.44x for Pharmaron Beijing. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGCRegencell Bioscience Holdings-- -- -- -- PHBBFPharmaron Beijing1.44x -- -- --
-
Which has Higher Returns RGC or PRE?
Prenetics Global has a net margin of -- compared to Regencell Bioscience Holdings's net margin of -137.21%. Regencell Bioscience Holdings's return on equity of -- beat Prenetics Global's return on equity of -23.16%.
Company Gross Margin Earnings Per Share Invested Capital RGCRegencell Bioscience Holdings-- -- -- PREPrenetics Global50.75% -$0.84 $180.1M -
What do Analysts Say About RGC or PRE?
Regencell Bioscience Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Prenetics Global has an analysts' consensus of $9.00 which suggests that it could grow by 59.43%. Given that Prenetics Global has higher upside potential than Regencell Bioscience Holdings, analysts believe Prenetics Global is more attractive than Regencell Bioscience Holdings.
Company Buy Ratings Hold Ratings Sell Ratings RGCRegencell Bioscience Holdings0 0 0 PREPrenetics Global1 0 0 -
Is RGC or PRE More Risky?
Regencell Bioscience Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Prenetics Global has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RGC or PRE?
Regencell Bioscience Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prenetics Global offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regencell Bioscience Holdings pays -- of its earnings as a dividend. Prenetics Global pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RGC or PRE?
Regencell Bioscience Holdings quarterly revenues are --, which are smaller than Prenetics Global quarterly revenues of $7.8M. Regencell Bioscience Holdings's net income of -- is lower than Prenetics Global's net income of -$10.7M. Notably, Regencell Bioscience Holdings's price-to-earnings ratio is -- while Prenetics Global's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regencell Bioscience Holdings is -- versus 2.72x for Prenetics Global. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGCRegencell Bioscience Holdings-- -- -- -- PREPrenetics Global2.72x -- $7.8M -$10.7M
-
Which has Higher Returns RGC or SBMFF?
Sino Biopharmaceutical has a net margin of -- compared to Regencell Bioscience Holdings's net margin of --. Regencell Bioscience Holdings's return on equity of -- beat Sino Biopharmaceutical's return on equity of 10.53%.
Company Gross Margin Earnings Per Share Invested Capital RGCRegencell Bioscience Holdings-- -- -- SBMFFSino Biopharmaceutical-- -- $7.1B -
What do Analysts Say About RGC or SBMFF?
Regencell Bioscience Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Sino Biopharmaceutical has an analysts' consensus of -- which suggests that it could fall by --. Given that Regencell Bioscience Holdings has higher upside potential than Sino Biopharmaceutical, analysts believe Regencell Bioscience Holdings is more attractive than Sino Biopharmaceutical.
Company Buy Ratings Hold Ratings Sell Ratings RGCRegencell Bioscience Holdings0 0 0 SBMFFSino Biopharmaceutical0 0 0 -
Is RGC or SBMFF More Risky?
Regencell Bioscience Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sino Biopharmaceutical has a beta of 0.538, suggesting its less volatile than the S&P 500 by 46.165%.
-
Which is a Better Dividend Stock RGC or SBMFF?
Regencell Bioscience Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sino Biopharmaceutical offers a yield of 2.49% to investors and pays a quarterly dividend of $0.00 per share. Regencell Bioscience Holdings pays -- of its earnings as a dividend. Sino Biopharmaceutical pays out 27.13% of its earnings as a dividend. Sino Biopharmaceutical's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RGC or SBMFF?
Regencell Bioscience Holdings quarterly revenues are --, which are smaller than Sino Biopharmaceutical quarterly revenues of --. Regencell Bioscience Holdings's net income of -- is lower than Sino Biopharmaceutical's net income of --. Notably, Regencell Bioscience Holdings's price-to-earnings ratio is -- while Sino Biopharmaceutical's PE ratio is 24.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regencell Bioscience Holdings is -- versus 1.97x for Sino Biopharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGCRegencell Bioscience Holdings-- -- -- -- SBMFFSino Biopharmaceutical1.97x 24.26x -- --
-
Which has Higher Returns RGC or UNBSF?
Uni-Bio Science Group has a net margin of -- compared to Regencell Bioscience Holdings's net margin of --. Regencell Bioscience Holdings's return on equity of -- beat Uni-Bio Science Group's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RGCRegencell Bioscience Holdings-- -- -- UNBSFUni-Bio Science Group-- -- -- -
What do Analysts Say About RGC or UNBSF?
Regencell Bioscience Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Uni-Bio Science Group has an analysts' consensus of -- which suggests that it could fall by --. Given that Regencell Bioscience Holdings has higher upside potential than Uni-Bio Science Group, analysts believe Regencell Bioscience Holdings is more attractive than Uni-Bio Science Group.
Company Buy Ratings Hold Ratings Sell Ratings RGCRegencell Bioscience Holdings0 0 0 UNBSFUni-Bio Science Group0 0 0 -
Is RGC or UNBSF More Risky?
Regencell Bioscience Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Uni-Bio Science Group has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock RGC or UNBSF?
Regencell Bioscience Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Uni-Bio Science Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regencell Bioscience Holdings pays -- of its earnings as a dividend. Uni-Bio Science Group pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RGC or UNBSF?
Regencell Bioscience Holdings quarterly revenues are --, which are smaller than Uni-Bio Science Group quarterly revenues of --. Regencell Bioscience Holdings's net income of -- is lower than Uni-Bio Science Group's net income of --. Notably, Regencell Bioscience Holdings's price-to-earnings ratio is -- while Uni-Bio Science Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regencell Bioscience Holdings is -- versus -- for Uni-Bio Science Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RGCRegencell Bioscience Holdings-- -- -- -- UNBSFUni-Bio Science Group-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
